Cargando…

Fasting plasma glucose level-based formula for estimating starting daily dose in basal-bolus insulin therapy

There is no standard formula for estimating the starting daily dose (SDD) of basal-bolus insulin therapy (BBT). We aimed to develop a formula for estimating SDD and evaluate its efficacy and safety in patients with type 2 diabetes hospitalized for BBT. In the first study (n = 104), we retrospectivel...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nagao, Mototsugu, Harada, Taro, Tanimura-Inagaki, Kyoko, Kobayashi, Shunsuke, Fukuda, Izumi, Sugihara, Hitoshi, Oikawa, Shinichi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9852227/ https://www.ncbi.nlm.nih.gov/pubmed/36658284 http://dx.doi.org/10.1038/s41598-023-28138-6

Ejemplares similares

Efficacy and safety of sitagliptin treatment in older adults with moderately controlled type 2 diabetes: the STREAM study
por: Nagao, Mototsugu, et al.
Publicado: (2023)

Multiple daily insulin injections ameliorate QT interval by lowering blood glucose levels in patients with type 2 diabetes
por: Kobayashi, Shunsuke, et al.
Publicado: (2021)

Frequency of Achilles Tendon Xanthoma in Patients with Acute Coronary Syndrome
por: Harada, Taro, et al.
Publicado: (2017)

Perioperative glycemic status is linked to postoperative complications in non-intensive care unit patients with type-2 diabetes: a retrospective study
por: Oba, Takeshi, et al.
Publicado: (2022)

Comparison of three α‐glucosidase inhibitors for glycemic control and bodyweight reduction in Japanese patients with obese type 2 diabetes
por: Sugihara, Hitoshi, et al.
Publicado: (2013)

Severity and multiplicity of microvascular complications are associated with QT interval prolongation in patients with type 2 diabetes
por: Kobayashi, Shunsuke, et al.
Publicado: (2017)

SAT-456 Reduced Cholesterol Absorption and Synthesis Markers in Patients with Hyperthyroidism Due to Graves’ Disease
por: Nagamine, Tomoko, et al.
Publicado: (2020)

MON-LB112 Socioeconomic Status, Literacy, and Sex Differences in the Progression of Retinopathy in Patients With Type 2 Diabetes in Tokyo, Japan
por: Emoto, Naoya, et al.
Publicado: (2020)

Insulin and heparin challenge tests are useful for choosing an optimal insulin regimen in a case of subcutaneous insulin resistance
por: Nakamura, Yuko, et al.
Publicado: (2020)

Different pathogenesis of glucose intolerance in two subtypes of primary aldosteronism: Aldosterone‐producing adenoma and idiopathic hyperaldosteronism
por: Okazaki‐Hada, Mikiko, et al.
Publicado: (2020)

Irrational Responses to Risk Preference Questionnaires by Patients with Diabetes with or without Retinopathy and Comparison with Those without Diabetes
por: Emoto, Naoya, et al.
Publicado: (2020)

Selective breeding of mice for different susceptibilities to high fat diet‐induced glucose intolerance: Development of two novel mouse lines, Selectively bred Diet‐induced Glucose intolerance‐Prone and ‐Resistant
por: Nagao, Mototsugu, et al.
Publicado: (2012)

Association of glycated albumin with the presence of carotid plaque in patients with type 2 diabetes
por: Sato, Yuki, et al.
Publicado: (2013)

Repetitive Glucose Spikes Accelerate Atherosclerotic Lesion Formation in C57BL/6 Mice
por: Shuto, Yuki, et al.
Publicado: (2015)

Metformin Attenuates Early-Stage Atherosclerosis in Mildly Hyperglycemic Oikawa-Nagao Mice
por: Asai, Akira, et al.
Publicado: (2019)

Characterization of Pancreatic Islets in Two Selectively Bred Mouse Lines with Different Susceptibilities to High-Fat Diet-Induced Glucose Intolerance
por: Nagao, Mototsugu, et al.
Publicado: (2014)

Postprandial Increase in Energy Expenditure Correlates with Body Weight Reduction in Patients with Type 2 Diabetes Receiving Diet Therapy
por: Sanoyama, Daisuke, et al.
Publicado: (2017)

A case of pheochromocytoma associated with liver abscess and intestinal pseudo-obstruction
por: Okazaki-Hada, Mikiko, et al.
Publicado: (2022)

FoxO1 breaks diabetic heart
por: Nagao, Mototsugu, et al.
Publicado: (2013)

Effect of Glycemic Control on Chylomicron Metabolism and Correlation between Postprandial Metabolism of Plasma Glucose and Chylomicron in Patients with Type 2 Diabetes Treated with Basal-bolus Insulin Therapy with or without Vildagliptin
por: Okajima, Fumitaka, et al.
Publicado: (2017)

The basal to total insulin ratio in outpatients with diabetes on basal-bolus regimen
por: Castellano, Elena, et al.
Publicado: (2018)

Basal–Bolus Insulin Therapy with Gla-300 During Hospitalization Reduces Nocturnal Hypoglycemia in Patients with Type 2 Diabetes Mellitus: A Randomized Controlled Study
por: Okajima, Fumitaka, et al.
Publicado: (2018)

Potential Protection Against Type 2 Diabetes in Obesity Through Lower CD36 Expression and Improved Exocytosis in β-Cells
por: Nagao, Mototsugu, et al.
Publicado: (2020)

Preventive effect of ipragliflozin on nocturnal hypoglycemia in patients with type 2 diabetes treated with basal‐bolus insulin therapy: An open‐label, single‐center, parallel, randomized control study
por: Okajima, Fumitaka, et al.
Publicado: (2016)

Correction to: The basal to total insulin ratio in outpatients with diabetes on basal-bolus regimen
por: Castellano, Elena, et al.
Publicado: (2018)

Switching from Twice-Daily Basal Insulin Injections to Once-Daily Insulin Degludec Injection for Basal-Bolus Insulin Regimen in Japanese Patients with Type 1 Diabetes: A Pilot Study
por: Tosaka, Yuka, et al.
Publicado: (2015)

Biphasic Insulin Aspart 30/70: Pharmacokinetics and Pharmacodynamics Compared With Once-Daily Biphasic Human Insulin and Basal-Bolus Therapy
por: Heise, Tim, et al.
Publicado: (2009)

Prenatal Nicotine Exposure Induces Low Birthweight and Hyperinsulinemia in Male Rats
por: Nemoto, Takahiro, et al.
Publicado: (2021)

Impact of Switching from Twice-Daily Basal Insulin to Once-Daily Insulin Glargine 300 U/mL in People with Type 1 Diabetes on Basal–Bolus Insulin: Phase 4 OPTIMIZE Study
por: Mathieu, Chantal, et al.
Publicado: (2020)

Effect of sodium-glucose cotransporter 2 inhibitor in patients with non-alcoholic fatty liver disease and type 2 diabetes mellitus: a propensity score-matched analysis of real-world data
por: Arai, Taeang, et al.
Publicado: (2021)

Initial Basal and Bolus Rates and Basal Rate Variability During Pump Treatment in Children and Adolescents
por: Demir, Günay, et al.
Publicado: (2021)

The Effect of Type and Daily Doses of Insulin to Treatment Success in Type 2 Diabetes Patients who are Receiving Basal-bolus Insulin Therapy
por: Ozturkmen, Yuksel Asli, et al.
Publicado: (2020)

Liver fibrosis is associated with carotid atherosclerosis in patients with liver biopsy-proven nonalcoholic fatty liver disease
por: Arai, Taeang, et al.
Publicado: (2021)

Antifibrotic effect and long‐term outcome of SGLT2 inhibitors in patients with NAFLD complicated by diabetes mellitus
por: Arai, Taeang, et al.
Publicado: (2022)

Accuracy of Bolus and Basal Rate Delivery of Different Insulin Pump Systems
por: Freckmann, Guido, et al.
Publicado: (2019)

Intensification of IDegAsp Twice Daily (Adding Insulin Aspart vs. Switching To Basal–Bolus): Exploratory Randomized Trial in Type 2 Diabetes
por: Bebakar, Wan Mohamaed Wan, et al.
Publicado: (2016)

The role of sulfonylurea plus basal insulin on glycemic variability compared to basal bolus regime in T2D patients
por: Freire, Paula Vieira, et al.
Publicado: (2015)

Making Sense of BGM and CGM Data for a Basal-Bolus Insulin User
Publicado: (2020)

A preliminary deep learning study on automatic segmentation of contrast-enhanced bolus in videofluorography of swallowing
por: Ariji, Yoshiko, et al.
Publicado: (2022)

Comparison of the efficacy and safety of insulin degludec/aspart (twice‐daily injections), insulin glargine 300 U/mL, and insulin glulisine (basal–bolus therapy)
por: Kawaguchi, Yuji, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_dk12b9rshscocs56ga212058j8